phase

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

2 months ago

Milano Cortina 2026 ramps up excitement as Italy enters final delivery phase

17 September 2025 - With just 70 days to go until the Olympic flame is lit in Olympia, Greece, the International…

2 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

2 months ago

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid…

2 months ago

CellPoint Digital Appoints Travel Technology Pioneers Julia Sattel and Kathleen Merrill to Board of Directors

Former Amadeus President and Southwest Airlines SVP & CIO Join Payment Orchestration Leader to Drive Next Phase of Travel Retailing…

2 months ago

Arkieva announces Anand Iyer as CEO

Supply chain planning veteran brings technical expertise, experience scaling go-to-market functions to lead company through next phase of growth WILMINGTON,…

2 months ago

Q&A WITH FX DEMAISON, GENESIS MAGMA RACING TECHNICAL DIRECTOR AND JUSTIN TAYLOR, GENESIS MAGMA RACING CHIEF ENGINEER

Genesis Magma Racing’s technical leads reflect on the busy first weeks of the GMR-001 Hypercar’s on-track development phase FX Demaison and…

3 months ago

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…

3 months ago

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

3 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

September 06, 2025 14:30 ET  | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…

3 months ago